Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Nagata Y, Kageyama S, Ishikawa T, Kokura S, Okayama T, Abe T, Murakami M, Otsuka K, Ariyoshi T, Kojima T, Taniguchi K, Kobayashi S, Shimada H, Yajima S, Suzuki T, Hirano S, Tsuchikawa T, Shichinohe T, Ueda S, Kanetaka K, Yoneda A, Wada H, Doki Y, Yamaue H, Katsuda M, Ohi M, Yasuda H, Kondo K, Kataoka M, Kodera Y, Koike M, Shiraishi T, Miyahara Y, Goshima N, Fukuda E, Yamaguchi K, Sato E, Ikeda H, Yamada T, Osako M, Hirai K, Miyamoto H, Watanabe T, Shiku H. Nagata Y, et al. Among authors: osako m. Cancer Immunol Immunother. 2022 Nov;71(11):2743-2755. doi: 10.1007/s00262-022-03194-5. Epub 2022 Apr 16. Cancer Immunol Immunother. 2022. PMID: 35429246 Free PMC article. Clinical Trial.
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. Kageyama S, et al. Among authors: osako m. J Transl Med. 2013 Oct 5;11:246. doi: 10.1186/1479-5876-11-246. J Transl Med. 2013. PMID: 24093426 Free PMC article. Clinical Trial.
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators. Fontana M, et al. N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2409134. Online ahead of print. N Engl J Med. 2024. PMID: 39213194
[Issues of transition support to adulthood and the practices of pediatric-adult healthcare transition in neurological diseases].
Ogata K, Mochizuki Y, Kumada S, Tomita S, Sakiyama Y, Kikuchi K, Hayakawa M, Osako M, Saito T, Mochizuki H; Special Committee on Measures for Transition from Pediatric to Adult Health Care, the Japanese Society of Neurology; Special Committee for Transition from Pediatric to Adult Health Care, the Japanese Society of Medical Networking for Intractable Diseases. Ogata K, et al. Among authors: osako m. Rinsho Shinkeigaku. 2024 Jul 27;64(7):460-464. doi: 10.5692/clinicalneurol.cn-001985. Epub 2024 Jun 22. Rinsho Shinkeigaku. 2024. PMID: 38910115 Japanese.
RANKL signaling drives skeletal muscle into the oxidative profile.
Cavalcanti de Araújo PH, Cezine MER, Vulczak A, Vieira LC, Matsuo FS, Remoto JM, Santos ADR, Miyabara EH, Alberici LC, Osako MK. Cavalcanti de Araújo PH, et al. Among authors: osako mk. J Bone Miner Res. 2024 Jul 23;39(6):753-764. doi: 10.1093/jbmr/zjae058. J Bone Miner Res. 2024. PMID: 38619281
171 results